SAT0356 The Therapeutic Efficacy of the Novel Uricosuric Agent UR-1102 for Hyperuricemia and Gout

2013 ◽  
Vol 72 (Suppl 3) ◽  
pp. A704.1-A704 ◽  
Author(s):  
S. O. Ahn ◽  
N. Horiba ◽  
S. Ohtomo ◽  
K. J. Lee ◽  
K. H. Kim ◽  
...  
Keyword(s):  
Therapeutic Efficacy ◽  
The Novel ◽  
Uricosuric Agent

Novel agents in development for the treatment of depression

CNS Spectrums ◽  
2013 ◽  
Vol 18 (s1) ◽  
pp. 34-41 ◽  
Author(s):  
Meghan M. Grady ◽  
Stephen M. Stahl
Keyword(s):  
Protein Synthesis ◽  
Hpa Axis ◽  
Therapeutic Efficacy ◽  
Novel Agents ◽  
The Novel ◽  
Glutamatergic Neurotransmission ◽  
Downstream Effects ◽  
Investigational Drugs ◽  
Treatment Of Depression ◽  
Hpa Axis Functioning

There are several investigational drugs in development for the treatment of depression. Some of the novel antidepressants in development target monoaminergic neurotransmission in accordance with the “monoamine hypothesis of depression.” However, the current conceptualization of antidepressant actions is that it is the downstream effects on protein synthesis and neuroplasticity that account for therapeutic efficacy, rather than the immediate effects on synaptic monoamine levels. Thus, a number of novel agents in development directly target components of this “neuroplasticity hypothesis of depression,” including hypothetically overactive glutamatergic neurotransmission and dysfunctional hypothalamic–pituitary–adrenal (HPA) axis functioning.

scholarly journals Immunogenic Cell Death by the Novel Topoisomerase I Inhibitor TLC388 Enhances the Therapeutic Efficacy of Radiotherapy

Cancers ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 1218
Author(s):  
Kevin Chih-Yang Huang ◽  
Shu-Fen Chiang ◽  
Pei-Chen Yang ◽  
Tao-Wei Ke ◽  
Tsung-Wei Chen ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Cell Death ◽  
Tumor Microenvironment ◽  
Distant Metastasis ◽  
Therapeutic Efficacy ◽  
Topoisomerase I ◽  
Locally Advanced ◽  
Immunogenic Cell Death ◽  
The Novel ◽  
Topoisomerase I Inhibitor

Rectal cancer accounts for 30–40% of colorectal cancer (CRC) and is the most common cancer-related death worldwide. The preoperative neoadjuvant chemoradiotherapy (neoCRT) regimen is the main therapeutic strategy for patients with locally advanced rectal cancer (LARC) to control tumor growth and reduce distant metastasis. However, 30–40% of patients achieve a partial response to neoCRT and suffer from unnecessary drug toxicity side effects and a risk of distant metastasis. In our study, we found that the novel topoisomerase I inhibitor lipotecan (TLC388) can elicit immunogenic cell death (ICD) to release damage-associated molecular patterns (DAMPs), including HMGB1, ANXA1, and CRT exposure. Lipotecan thereby increases cancer immunogenicity and triggers an antitumor immune response to attract immune cell infiltration within the tumor microenvironment (TME) in vitro and in vivo. Taken together, these results show that lipotecan can remodel the tumor microenvironment to provoke anticancer immune responses, which can provide potential clinical benefits to the therapeutic efficacy of neoCRT in LARC patients.

scholarly journals Therapeutic Efficacy of the Novel Stimuli-Sensitive Nano-Ferritins Containing Doxorubicin in a Head and Neck Cancer Model

2017 ◽  
Vol 18 (7) ◽  
pp. 1555 ◽  
Author(s):  
Verena Damiani ◽  
Elisabetta Falvo ◽  
Giulio Fracasso ◽  
Luca Federici ◽  
Martina Pitea ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Therapeutic Efficacy ◽  
The Novel ◽  
Cancer Model ◽  
Stimuli Sensitive

scholarly journals Efficacy of a novel topical combination of esafoxolaner, eprinomectin and praziquantel against Notoedres cati mange in cats

Parasite ◽  
2021 ◽  
Vol 28 ◽  
pp. 27
Author(s):  
Martin Knaus ◽  
Balázs Capári ◽  
Mirjam Szabó ◽  
Katrin Kley ◽  
Chris Johnson
Keyword(s):  
Body Weight ◽  
Therapeutic Efficacy ◽  
Clinical Success ◽  
Clinical Signs ◽  
Mineral Oil ◽  
Placebo Control ◽  
The Novel ◽  
Single Spot ◽  
Notoedres Cati ◽  
Controlled Clinical Study

The therapeutic efficacy against notoedric mange of a topical combination of esafoxolaner, eprinomectin and praziquantel (Nexgard® Combo, Boehringer Ingelheim) was evaluated in a masked, controlled clinical study including 14 cats with natural or induced Notoedres cati infestation. Cats were allocated randomly to two groups of seven cats each, to be administered either mineral oil (placebo control) or NexGard® Combo. Each treatment was administered once as spot-on at 0.12 mL per kg body weight (representing the minimum label dosage of NexGard® Combo, i.e. 1.44 mg esafoxolaner, 0.48 mg eprinomectin, and 10.0 mg praziquantel per kg body weight). Live mites were counted in skin scrapings collected within seven days prior to and 14, 27/28, 42 and 56 days after treatment to calculate the percentage efficacy of NexGard® Combo based on the comparison of mean live mite counts of the two groups. Concurrently, mange lesions and clinical signs were scored to establish a clinical success valuation. No live mites were recovered from any NexGard® Combo-treated cats post-treatment, indicating 100% therapeutic efficacy following a single spot-on administration of the novel antiparasitic combination. The clinical success valuations in the NexGard® Combo-treated cats were 14.3%, 42.8%, 100% and 100% at 14, 27/28, 42 and 56 days after treatment, respectively. No health problems were observed throughout the study.

The novel steroidal glycoside from the dried bulb of Allium Macrostemon Bunge inhibits platelet activation

2010 ◽  
Vol 34 (8) ◽  
pp. S33-S33
Author(s):  
Wenchao Ou ◽  
Haifeng Chen ◽  
Yun Zhong ◽  
Benrong Liu ◽  
Keji Chen
Keyword(s):  
Platelet Activation ◽  
The Novel ◽  
Steroidal Glycoside ◽  
Allium Macrostemon
Sign in / Sign up

Export Citation Format

Share Document